Bio-Rad Laboratories (NYSE:BIO) Stock Price Target Raised at Royal Bank Of Canada

Bio-Rad Laboratories (NYSE:BIO) had its price target upped by equities researchers at Royal Bank Of Canada from $390.00 to $440.00 in a research note issued to investors on Thursday, Benzinga reports. The firm currently has an “outperform” rating on the medical research company’s stock. Royal Bank Of Canada‘s price objective would indicate a potential upside of 19.08% from the company’s previous close.

Several other equities research analysts have also commented on BIO. Zacks Research raised shares of Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, August 11th. Weiss Ratings raised shares of Bio-Rad Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, October 8th. Citigroup increased their price target on shares of Bio-Rad Laboratories from $300.00 to $330.00 and gave the company a “hold” rating in a research note on Wednesday, August 5th. Finally, Wells Fargo & Company upped their price target on Bio-Rad Laboratories from $310.00 to $330.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Bio-Rad Laboratories has an average rating of “Hold” and an average price target of $366.67.

Bio-Rad Laboratories Trading Down 2.8%

Shares of BIO traded down $10.50 during trading hours on Thursday, reaching $369.49. 224,849 shares of the company traded hands, compared to its average volume of 305,727. The firm has a market cap of $9.88 billion, a price-to-earnings ratio of 44.91 and a beta of 1.06. Bio-Rad Laboratories has a 12-month low of $236.73 and a 12-month high of $396.23. The stock’s fifty day moving average price is $374.31 and its 200 day moving average price is $314.89. The company has a current ratio of 3.14, a quick ratio of 2.33 and a debt-to-equity ratio of 0.11.

Bio-Rad Laboratories (NYSE:BIO) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.23 by $0.42. Bio-Rad Laboratories had a net margin of 8.59% and a return on equity of 3.54%. The firm had revenue of $656.40 million for the quarter, compared to the consensus estimate of $649.94 million. During the same period last year, the firm earned $2.26 earnings per share. The company’s quarterly revenue was up .5% on a year-over-year basis. Sell-side analysts forecast that Bio-Rad Laboratories will post 9.71 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Assenagon Asset Management S.A. increased its stake in Bio-Rad Laboratories by 57.8% during the 2nd quarter. Assenagon Asset Management S.A. now owns 233,227 shares of the medical research company’s stock worth $68,478,000 after buying an additional 85,393 shares during the period. Wellington Management Group LLP acquired a new stake in Bio-Rad Laboratories during the 2nd quarter worth approximately $17,690,000. Hound Partners LLC boosted its position in Bio-Rad Laboratories by 125.9% in the 1st quarter. Hound Partners LLC now owns 97,724 shares of the medical research company’s stock valued at $27,241,000 after buying an additional 54,456 shares during the period. Amundi boosted its position in Bio-Rad Laboratories by 1,763.4% in the 1st quarter. Amundi now owns 38,778 shares of the medical research company’s stock valued at $10,809,000 after buying an additional 36,697 shares during the period. Finally, Lazard Asset Management LLC purchased a new position in Bio-Rad Laboratories in the 1st quarter valued at approximately $5,098,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Key Headlines Impacting Bio-Rad Laboratories

Here are the key news stories impacting Bio-Rad Laboratories this week:

• Positive Sentiment: Bio-Rad reported Q3 earnings of $2.65 per share, above estimates, while revenue of $656.4 million also exceeded expectations. EPS rose from $2.26 a year earlier, though revenue increased just 0.5%. Article: Bio-Rad Laboratories Q3 Earnings Top Estimates
• Positive Sentiment: The company expanded its oncology assay menu for QX700 digital droplet PCR systems, adding to its product offering. Article: Bio-Rad Expands Oncology Assay Menu for QX700 ddPCR Systems
• Negative Sentiment: Bio-Rad reaffirmed 2026 currency-neutral revenue growth guidance of -3% to 0.5%, signaling limited near-term sales growth. It did target the upper half of its 10%–12% non-GAAP operating-margin range, which offers some support, but the restrained revenue outlook may temper the earnings beat. Article: Bio-Rad Reaffirms 2026 Revenue Growth and Margin Targets

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc develops, manufactures and markets products and systems used in life science research and clinical diagnostics. Its life science portfolio includes laboratory instruments, reagents, software and consumables used in areas such as genomics, proteomics, cell biology, biopharmaceutical development and quality control.

The company’s clinical diagnostics business provides systems, reagents and software for blood typing, infectious disease testing, diabetes monitoring, quality control and other diagnostic applications.